SCHEMBL5380661

SCHEMBL5380661

Cc1ccc(S(=O)(=O)Nc2ccc(SCc3nc4cc(F)cc(F)c4s3)cc2)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
GFER P55789 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 4/20 0.38
HTT P42858 3/20 0.38
PKM P14618 1/20 0.38
NOD2 Q9HC29 1/20 0.38
CASP6 P55212 1/20 0.37
GAA P10253 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
GPR27 Q9NS67 1/20 0.36
AKR1B1 P15121 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376794 0.92 POLB (0.41) POLBSMN1; SMN2LMNAHTTGAA
SCHEMBL5376865 0.87 POLB (0.47) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5370583 0.86 POLB (0.48) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5380764 0.80 TRPV1 (0.57) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5380338 0.80 POLB (0.56) POLBGFERSMN1; SMN2LMNAPKM
SCHEMBL5378671 0.79 TRPV1 (0.45) POLBSMN1; SMN2LMNAHTTPKM
SCHEMBL5368347 0.78 POLB (0.42) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5386741 0.78 POLB (0.56) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5391181 0.77 POLB (0.54) POLBGFERSMN1; SMN2LMNAHTT
SCHEMBL5371921 0.75 POLB (0.53) POLBGFERSMN1; SMN2LMNACASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP claimed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US claimed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US claimed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO claimed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885GFER 3619/4885SMN1; SMN2 3404/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885GFER 2976/4885SMN1; SMN2 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.